Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer

BACKGROUND: Anti-PD-1 and PD-L1 antibodies (mAbs) are approved immunotherapy agents to treat metastatic non-small cell lung cancer (NSCLC) patients. Only a minority of patients responds to these treatments and biomarkers predicting response are currently lacking. METHODS: Immunoscore-Immune-Checkpoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghiringhelli, François, Bibeau, Frederic, Greillier, Laurent, Fumet, Jean-David, Ilie, Alis, Monville, Florence, Laugé, Caroline, Catteau, Aurélie, Boquet, Isabelle, Majdi, Amine, Morgand, Erwan, Oulkhouir, Youssef, Brandone, Nicolas, Adam, Julien, Sbarrato, Thomas, Kassambara, Alboukadel, Fieschi, Jacques, Garcia, Stéphane, Lepage, Anne Laure, Tomasini, Pascale, Galon, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232659/
https://www.ncbi.nlm.nih.gov/pubmed/37244159
http://dx.doi.org/10.1016/j.ebiom.2023.104633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232659/
https://www.ncbi.nlm.nih.gov/pubmed/37244159
http://dx.doi.org/10.1016/j.ebiom.2023.104633

Ejemplares similares